NewAmsterdam Pharma Company N.V.
NAMS•NASDAQ•Healthcare•Biotechnology

About NewAmsterdam Pharma Company

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOMichael Davidson
Founded2019
Employees68
CountryNetherlands
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Corporate Identifiers

CIK0001936258
ISINNL00150012L7
SIC2834

Leadership Team & Key Executives

Dr. Michael Harvey Davidson FACC, Facp., M.D.
Chief Executive Officer, President and Executive Board Member
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.
Founder, Chief Scientific Officer, Member of Executive Board and Director
Mayur Amrat Somaiya
Chief Financial Officer
Douglas F. Kling
Chief Operating Officer
Juliette Audet M.B.A., M.Sc.
Chief Strategy and Business Officer
Louise Kooij
Chief Accounting Officer
Matthew Philippe
Executive Vice President &Head of Investor Relations
Bob Rambo
Executive Vice President of Marketing
Maryellen McQuade
Chief People Officer
Dr. Marc Ditmarsch M.D.
Chief Development Officer